Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
Inventors
Narasimhan, Rangachari • Belardinelli, Luiz • Schuler, Carlos A.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10010294-B2
Publication Date
2018-07-03
Expiration Date
Abstract
Disclosed herein are methods of treating cardiac arrhythmia with electronic monitoring in a timely manner. Also disclosed herein are systems for electronic monitoring of cardiac arrhythmia.
Core Innovation
The invention relates to treating cardiac arrhythmia in a subject by combining electronic monitoring with rapid self-administered inhaled antiarrhythmic therapy. Cardiac arrhythmia is identified with the aid of an electronic monitoring device, and the monitoring device provides instruction for administering an aerosolized pharmaceutical composition. The aerosolized composition is administered to thereby treat the cardiac arrhythmia.
The therapy is delivered by aerosolizing a pharmaceutical composition in less than about 9 minutes using an inhaler. The pharmaceutical composition comprises a therapeutically effective amount of at least one antiarrhythmic or a pharmaceutically acceptable salt thereof. The document further describes treating the arrhythmia with conversion to normal sinus rhythm within a defined post-administration time window.
The disclosed treatment approach is supported by an integrated system architecture in which an electronic monitoring chip monitors incidence of arrhythmia and communicates wirelessly with an electronic monitoring device. The electronic monitoring device communicates with the inhaler so that monitoring and administering are coordinated. The monitoring device can include output interfaces such as a digital display and auditory means, and it can be implemented as a smartphone with storage means for subject data.
Claims Coverage
The independent claim set includes 2 independent claims. Across these, the claims cover an integrated monitoring-and-inhalation treatment method and a corresponding system architecture, with the key inventive features centering on rapid inhalation timing, electronic arrhythmia identification, and coordinated device-to-inhaler communication/instruction.
Monitoring-guided inhaled treatment of cardiac arrhythmia
A method of treating cardiac arrhythmia in a subject includes identifying cardiac arrhythmia with the aid of an electronic monitoring device, aerosolizing a pharmaceutical composition in less than about 9 minutes using an inhaler, administering the aerosolized pharmaceutical composition to treat the cardiac arrhythmia, and wherein the electronic monitoring device provides instruction for the administering.
Wireless monitoring chip, monitoring device, and inhaler communication
A system comprises an electronic monitoring chip that monitors incidence of arrhythmia in a subject, an electronic monitoring device in wireless communication with the electronic monitoring chip, and an inhaler wherein the electronic monitoring device is in communication with the inhaler.
Overall, the claims require electronic arrhythmia identification that drives instruction for administering a rapidly aerosolized antiarrhythmic via an inhaler, and a system architecture that links an arrhythmia monitoring chip to an electronic monitoring device and further to an inhaler via wireless communication and device-to-inhaler communication.
Stated Advantages
Rapid aerosolization for administration in less than about 9 minutes.
Therapeutically effective amount that converts a cardiac arrhythmia to normal sinus rhythm within about 0 seconds to about 2 hours after the administration.
Coordinated monitoring and administration because the electronic monitoring device provides instruction for administering the aerosolized pharmaceutical composition.
Documented Applications
No documented applications found
Interested in licensing this patent?